The Frazier Life Sciences team invests in and builds companies developing and commercializing novel therapeutics at all stages, from company formation to publics.
Frazier Life Sciences Closes $987 Million Venture Fund to Invest in Companies Developing Novel Biopharmaceuticals
Sanofi completes acquisition of Amunix
Blueprint Medicines Completes Acquisition of Lengo Therapeutics
Frazier Healthcare Partners Closes Oversubscribed $830 Million Life Sciences Public Fund